公开(公告)号：US10808039B2

公开(公告)日：2020-10-20

申请号：US16507839

申请日：2019-07-10

申请人： SEATTLE GENETICS, INC

发明人： Svetlana O. Doronina ,  Peter D. Senter ,  Brian E. Toki ,  Toni Beth Kline

IPC分类号： C07K16/32 ,  C07K7/02 ,  A61K47/68 ,  A61K38/00 ,  A61K39/00

摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

公开(公告)号：US20200347149A1

公开(公告)日：2020-11-05

申请号：US16933349

申请日：2020-07-20

申请人： Seattle Genetics, Inc.

发明人： Svetlana O. DORONINA ,  Peter D. SENTER ,  Brian E. Toki ,  Toni Beth KLINE

IPC分类号： C07K16/32 ,  C07K7/02 ,  A61K47/68

摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

公开(公告)号：US10414826B2

公开(公告)日：2019-09-17

申请号：US15811190

申请日：2017-11-13

申请人： SEATTLE GENETICS, INC.

发明人： Svetlana O. Doronina ,  Peter D. Senter ,  Brian E. Toki ,  Toni Beth Kline

IPC分类号： C07K7/02 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  C07K16/32

摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

公开(公告)号：US20170000897A1

公开(公告)日：2017-01-05

申请号：US15188843

申请日：2016-06-21

申请人： SEATTLE GENETICS, INC.

发明人： Svetlana O. Doronina ,  Peter D. Senter ,  Brian E. Toki ,  Toni Beth Kline

IPC分类号： A61K47/48 ,  C07K16/32

CPC分类号： C07K16/32 ,  A61K38/00 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K2039/505 ,  C07K7/02 ,  C07K2317/24 ,  Y02A50/414 ,  Y02A50/423 ,  Y02A50/469 ,  Y10T428/13

摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

摘要翻译： 制备包括MeVal-Val-Dil-Dap-Norephedrine（MMAE）和MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽，并通过各种接头包括马来酰亚胺酰基val-cit-PAB连接到配体上。 所得配体药物偶联物在体外和体内都是活性的。

公开(公告)号：US20140220047A1

公开(公告)日：2014-08-07

申请号：US14194106

申请日：2014-02-28

申请人： Seattle Genetics, Inc.

发明人： Svetlana O. Doronina ,  Peter D. Senter ,  Brian E. Toki ,  Toni Beth Kline

IPC分类号： A61K47/48

CPC分类号： C07K16/32 ,  A61K38/00 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K2039/505 ,  C07K7/02 ,  C07K2317/24 ,  Y02A50/414 ,  Y02A50/423 ,  Y02A50/469 ,  Y10T428/13

摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

摘要翻译： 制备包括MeVal-Val-Dil-Dap-Norephedrine（MMAE）和MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽，并通过各种接头包括马来酰亚胺酰基val-cit-PAB连接到配体上。 所得配体药物偶联物在体外和体内都是活性的。